[{"id":"ad11f149-0ac3-4e5e-9a2c-090277fc61cc","acronym":"CRC-403","url":"https://clinicaltrials.gov/study/NCT05169489","created_at":"2021-12-27T15:54:15.732Z","updated_at":"2025-02-25T17:01:36.333Z","phase":"Phase 1/2","brief_title":"A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)","source_id_and_acronym":"NCT05169489 - CRC-403","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bbT369"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/24/2022","start_date":" 01/24/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-03"}]